Semaglutide vs. Tirzepatide: A Patient Guide to Medical Weight Loss
A patient guide to semaglutide, tirzepatide, eligibility, coverage questions, and why medical supervision matters.
Moses Medical Editorial Team
May 1, 2026
If you live in the Bronx and you’ve been paying attention to anything health-related over the past two years, you’ve heard the names: Ozempic, Wegovy, Mounjaro, Zepbound. These GLP-1 receptor agonist medications have fundamentally changed the conversation around weight loss — moving it from willpower-based dieting into evidence-based medicine where it belongs. But with so many brand names, conflicting social media advice, and real questions about cost and access, it can be hard to know what actually applies to you.
This guide gives straight answers about GLP-1 medications, eligibility, coverage questions, and why medical supervision matters. It is not a promise that a medication will be right for every patient.
What Are GLP-1 Medications, and Why Do They Work?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally produces after eating. It signals your brain that you’re full, slows stomach emptying, and helps regulate blood sugar. Both semaglutide and tirzepatide are injectable medications that mimic this hormone, but they do it at therapeutic levels far beyond what your body produces on its own.
Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss) targets the GLP-1 receptor. Clinical trials showed an average weight loss of about 15% of body weight over 68 weeks — that’s roughly 35 pounds for someone starting at 230.
Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight loss) targets both the GLP-1 and GIP receptors. This dual mechanism produced even more impressive results in trials: an average of 21% body weight loss, with some patients losing over 25%. For a 230-pound patient, that could mean 48 pounds or more.
Both medications are administered as once-weekly subcutaneous injections, typically in the abdomen or thigh.
Head-to-Head: How They Compare
| Semaglutide (Wegovy) | Tirzepatide (Zepbound) | |
|---|---|---|
| Mechanism | GLP-1 only | GLP-1 + GIP (dual) |
| Average weight loss | ~15% | ~21% |
| Injection frequency | Weekly | Weekly |
| Dose titration | 4 escalating doses over 16 weeks | 4 escalating doses over 16 weeks |
| Common side effects | Nausea, constipation, diarrhea | Nausea, diarrhea, reduced appetite |
| FDA-approved for weight loss | Yes (Wegovy) | Yes (Zepbound) |
Both medications can be effective, but the right choice depends on the patient. Some people respond better to semaglutide. Others see more progress with tirzepatide. Patients with type 2 diabetes may benefit from tirzepatide’s stronger glucose-lowering effects. The point is that this is a clinical decision, not a five-minute questionnaire.
Who Qualifies?
At Moses Medical, we follow evidence-based criteria for prescribing GLP-1 medications:
- BMI of 30 or higher (obesity), or
- BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea
We also consider patients with metabolic syndrome, PCOS, or fatty liver disease on a case-by-case basis. Before starting medication, every patient gets a thorough evaluation that includes:
- Complete metabolic panel and lipid profile (done in our on-site lab — no separate appointment needed)
- HbA1c and fasting glucose
- Thyroid function tests
- Kidney function assessment
- Review of current medications for interactions
- Honest conversation about goals, timeline, and lifestyle
For patients who have tried multiple medications without success, pharmacogenomic testing can help identify why standard treatments may not be working.
What Medicaid Covers — and What It Doesn’t
This is where it gets real for the Bronx. The majority of our patients are on Medicaid managed care plans — MetroPlus, Fidelis Care, Amerigroup, and others. Coverage for GLP-1 medications varies significantly by plan and by the specific indication.
For type 2 diabetes: Most Medicaid plans cover semaglutide (Ozempic) and tirzepatide (Mounjaro) with prior authorization. Your provider needs to document that you’ve tried and failed metformin or another first-line agent.
For weight loss specifically: Coverage is more limited. Wegovy and Zepbound carry higher list prices, and not all Medicaid managed care plans cover them for the obesity indication alone. However, the landscape is improving. Several plans have expanded formulary access in 2025-2026, and our team stays current on which plans are approving what.
What we do at Moses Medical: We help gather the documentation each plan requires and explain what happens if a request is denied. If your plan will not cover a branded medication, we can discuss other cost and treatment questions when clinically appropriate. For a breakdown of MetroPlus, Fidelis, and other Medicaid managed care plans, see our Medicaid coverage guide.
Why a Supervised Program Matters
The internet has made it disturbingly easy to get these medications without proper oversight. Compounding pharmacies, overseas suppliers, and cash-pay telehealth startups are all selling variations of semaglutide and tirzepatide to anyone with a credit card. This is risky for several reasons:
- No baseline labs means potential thyroid, kidney, or pancreatic issues go undetected
- No dose titration means more severe side effects (pancreatitis is rare but serious)
- No ongoing monitoring means metabolic improvements aren’t tracked or optimized
- No nutritional support means the weight comes back when you stop the medication
A supervised medical weight loss program may include regular visits, lab monitoring through our on-site laboratory, nutrition counseling, and clear conversations about what happens if you taper or stop the medication. The visit may also address conditions that often travel alongside obesity, including hypertension, prediabetes, joint pain, and sleep apnea. Patients with uncontrolled blood pressure should also consider a cardiology evaluation. Heart disease and obesity share many of the same risk factors.
The On-Site Lab Advantage
One thing that sets Moses Medical apart: you don’t need to go to a separate lab for bloodwork. Our in-house lab means we can run your metabolic panel, A1c, liver enzymes, and kidney function during the same visit. Results come back faster, follow-up happens sooner, and nothing falls through the cracks. For patients on GLP-1 medications, regular lab monitoring isn’t optional — it’s how we keep you safe and adjust your plan in real time.
What a Realistic Timeline Looks Like
Patients should know the same thing before starting: this is not a quick fix. Here is what to expect:
- Weeks 1-4: Dose titration begins. Appetite changes are usually the first noticeable effect. Mild nausea is common and typically improves.
- Months 1-3: Most patients lose 5-8% of their starting weight. Energy improves. Blood sugar and blood pressure often begin to normalize.
- Months 3-6: Weight loss continues steadily. This is where tirzepatide often pulls ahead of semaglutide in total percentage lost.
- Months 6-12+: Weight stabilizes at a new baseline. The goal shifts to maintenance, metabolic health optimization, and building habits that sustain the progress.
Take the First Step
If you’ve been struggling with your weight and wondering whether these medications might be right for you, the honest answer is: maybe. The only way to know is to sit down with a provider who will evaluate your full picture — not sell you a subscription.
At Moses Medical, we accept many Medicaid and Medicare plans, including MetroPlus and Fidelis Care. Book a medical weight loss visit or call (646) 741-2111 if you want help reviewing coverage before you come in. We’re at 871B Westchester Ave in the Bronx, near the 2 and 5 trains at Simpson Street.
